1.Karataş, G, Tamam, L, Ozpoyraz, N. Gabapentin in the treatment of anxiety disorders. Bull Clin Psychopharmacol 2003;13:37–42.
2.Young, LT, Robb, JC, Hasey, GMet al.Gabapentin as an adjunctive treatment in bipolar disorder. J Affect Disord 1999;55:73–77.
3.Egashira, T, Inoue, T, Shirai, Y, Iwata, K, Honma, J, Koyama, T. Adjunctive gabapentin for treatment-resistant insomnia of bipolar disorder: a case report. Clin Neuropharmacol 2011;34:129–130.
4.Wettermark, B, Brandt, L, Kieler, H, Bodén, R. Pregabalin is increasingly prescribed for neuropathic pain, generalised anxiety disorder and epilepsy but many patients discontinue treatment. Int J Clin Pract 2014;68:104–110.
5.Darbà, J, Kaskens, L, Pérez, C, Álvarez, E, Navarro-Artieda, R, Sicras-Mainar, A. Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective. Adv Ther 2014;31:1–29.
6.Tassone, DM, Boyce, E, Guyer, J, Nuzum, D. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007;29:26–48.
7.Calza, A, Sogliani, C, Santoru, Fet al.Neonatal exposure to estradiol in rats influences neuroactive steroid concentrations, GABAA receptor expression, and behavioral sensitivity to anxiolytic drugs. J Neurochem 2010;113:1285–1295.
8.Smith, SS. α4βδ GABAA receptors and tonic inhibitory current during adolescence: effects on mood and synaptic plasticity. Front Neural Circuits 2013;7:135.
9.Gulinello, M, Gong, QH, Smith, SS. Progesterone withdrawal increases the anxiolytic actions of gaboxadol: role of α4βδ GABAA receptors. Neuroreport 2003;14:43–46.
10.de-Paris, F, Sant’Anna, MK, Vianna, MRet al.Effects of gabapentin on anxiety induced by simulated public speaking. J Psychopharmacol 2003;17:184–188.
11.Kulkarni, SK, Singh, K, Bishnoi, M. Comparative behavioural profile of newer antianxiety drugs on different mazes. Indian J Exp Biol 2008;46:633–638.
12.de-Paris, F, Busnello, JV, Vianna, MRet al.The anticonvulsant compound gabapentin possesses anxiolytic but not amnesic effects in rats. Behav Pharmacol 2000;11:169–173.
13.Valente, MM, Bortolotto, V, Cuccurazzu, Bet al.α2δ ligands act as positive modulators of adult hippocampal neurogenesis and prevent depression-like behavior induced by chronic restraint stress. Mol Pharmacol 2012;82:271–280.
14.Pellow, S, Chopin, P, File, SE, Briley, M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14:149–167.
15.Porsolt, RD, Anton, G, Blavet, N, Jalfre, M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379–391.
16.Pollack, MH, Matthews, J, Scott, EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry 1998;155:992–993.
17.Foye, W. Central nervous system depressants: sedative-hypnotics, benzodiazepines. In: William O. Foye, editor. Principles of Medicinal Chemistry, 3rd edn. Pennsylvania, PA: Lea and Febiger, 1989. p. 165–166.
18.Kayaalp, O. Antiepileptik İlaçlar. In: Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, vol. 2. Ankara, 2009. p. 884–901.
19.Gilman, GA, Goodman, S, Rail, T, Mured, F. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. USA: McGraw-Hill, 2006; p. 339–351.
20.Patty, F, Trivedi, MH, Fulton, M, Rush, AJ. Benzodiazepines as antidepressant: does GABA play a role in depression? Biol Psychiatry 1995;38:578–591.
21.Furukawa, TA, Streiner, D, Young, LT, Kinosta, Y. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2000;4:CD001026.
22.Feighner, JP. Overview of antidepressants currently used to treat anxiety disorders. J Clin Psychiatry 1999;60:18–22.
23.Parra, A, Everss, E, Monleon, S, Vinader-Caerols, C, Arenas, MC. Effects of acute amitriptyline administration on memory, anxiety and activity in male and female mice. Neurosci Res Commun 2002;31:135–144.
24.Everss, E, Arenas, MC, Vinader-Caerols, C, Monleon, S, Parra, A. Piracetam counteracts the effects of amitriptyline on inhibitory avoidance in CD1 mice. Behav Brain Res 2005;159:235–242.
25.Weinstock, M, Poltyrev, V, Bejar, C, Youdim, MB. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rats models of anxiety and depression. Psychopharmacology 2002;160:318–324.
26.Bilkei-Gorzo, A, Gyertyan, I, Levay, G. mCPP-induced anxiety in the light-dark box in rats: a new method for screening anxiolytic activity. Psychopharmacology (Berl) 1998;136:291–298.
27.Bodnoff, SR, Suranyi-Cadotte, B, Quirion, R, Meaney, MJ. A comparison of the effects of diazepam versus several typical and atypical antidepressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 1989;97:277–279.
28.Bodnoff, SR, Suranyi-Cadotte, B, Aitken, DH, Meaney, MJ. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 1998;95:298–302.
29.Askin, R, Turan, M, Cilli, AS, Kaya, N. Clomipramine versus sertraline in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1997;7:228–229.
30.Rao, D, Tovar, M, Oseroff, SBet al.Crystal-field and exchange interactions of dilute Gd+3 ions in Eu2CuO4. Phys Rev B Condens Matter 1988;38:8920–8922.
31.Javitt, DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984–997.
32.Krystal, JH, D’Souza, DC, Petrakis, ILet al.NMDA agonists and antagonists as probes of glutamatergic dsyfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999;7:125–143.
33.Vizi, ES. Role of high-affinity receptors and membrane transporters in nonsynaptic communication and drug action in central nervous system. Pharmacol Rev 2000;52:63–90.
34.Engin, E, Treit, D, Dickson, CT. Anxiolytic and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience 2009;161:359–369.
35.Engin, E, Treit, D, Dickson, CT. Corrigendum to ‘anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models’. Neuroscience 2009;162:1438–1439.
36.Maeng, S, Carlos, A, Zarate, JRet al.Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008;63:349–352.
37.Pirrenger, C, Sanacora, G, Krystal, JH. The NMDA receptor as a therapeutic target in major depressive disorders. CNS Neurol Disord Drug Targets 2007;6:101–115.
38.Phelps, LE, Brutsche, N, Moral, JR. Family history of alcohol dependence and initial antidepressant response to an NMDA antagonist. Biol Psychiatry 2008;65:181–184.